AlzeCure Pharma AB (DE:AC6)
FRANKFURT:AC6
AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.11 - €0.44
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€17.80M
Enterprise Value€149.56M
Total Cash (Recent Filing)€50.34M
Total Debt (Recent Filing)€5.12M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding114,914,450
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest debt and low leverage materially reduce near-term solvency and interest burden, giving management durable flexibility to fund clinical programs via non-debt routes. Over the next 2–6 months this lowers catastrophic financing risk and preserves options for partnerships or equity raises.
Focused CNS Drug Development PipelineA clear, specialized focus on CNS and Alzheimer’s small-molecule development supports a durable competitive position: specialized expertise increases attractiveness for licensing and co-development, and well-defined assets make strategic partnering or milestone monetization more feasible long-term.
Improving Free Cash Flow TrendAn improvement in free cash flow trajectory, even while still negative, signals rising operational efficiency or milestone receipts. Sustained improvement can extend runway, lessen near-term financing dependence, and strengthen bargaining power with partners over the coming months.
Bears Say
No Revenue And Recurring LossesA pre-commercial profile with no revenue and widening annual losses is a structural risk: persistent negative profitability erodes capital, forces repeated external financing, and implies a long path to self-sustaining operations unless clinical assets are monetized or licensed.
Consistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow creates an enduring funding need that limits strategic flexibility. Over several months this raises dilution risk from capital raises, can constrain ability to progress trials, and may force timing-dependent partnership or licensing deals on unfavorable terms.
Eroding Equity Increases Funding VulnerabilityA materially reduced equity buffer weakens the company’s ability to absorb clinical setbacks or extend programs without fresh capital. This structural erosion raises the likelihood of dilutive financing or asset sales, reducing long-term upside for existing investors and partners.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.11 and its highest was €0.44 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €17.80M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 33 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 114,914,450 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.